Purple Biotech Ltd (PPBT)
NASDAQ: PPBT · Real-Time Price · USD
0.489
+0.029 (6.30%)
At close: Aug 30, 2024, 4:00 PM
0.480
-0.009 (-1.84%)
After-hours: Aug 30, 2024, 4:15 PM EDT
Purple Biotech Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
20
Market Cap
13.01M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionPPBT News
- 1 day ago - Purple Biotech to Participate at H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewsWire
- 15 days ago - Purple Biotech Reports Second Quarter 2024 Financial Results and Business Highlights - GlobeNewsWire
- 5 weeks ago - Purple Biotech Receives Extension to Regain Compliance with the Nasdaq's Minimum Bid Price Rule - GlobeNewsWire
- 7 weeks ago - Purple Biotech to Host Virtual KOL Event to Discuss Positive Interim Results from Phase 2 Pancreatic Cancer Study with CM24 on July 11, 2024 - GlobeNewsWire
- 2 months ago - Purple Biotech Announces Closing of Exercise of Warrants for $2 Million Gross Proceeds - GlobeNewsWire
- 2 months ago - Purple Biotech Announces Exercise of Warrants for $2 Million Gross Proceeds - GlobeNewsWire
- 2 months ago - Purple Biotech Reports Additional Positive Interim Results from its Randomized Phase 2 Pancreatic Cancer Study with CM24 Regarding a Potential Predictive Biomarker for Overall Survival Benefit - GlobeNewsWire
- 3 months ago - Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and other Efficacy Endpoints in Pancreatic Cancer - GlobeNewsWire